Background: Phosphatidylserine (PS) is an anionic phospholipid primarily localized on the inner plasma membrane of healthy cells. In contrast, PS is externally expressed on cancer cells and tumor-associated vascular cells. PS is further externalized by treatment with GEM, a drug commonly used to treat advanced PDAC, the fourth leading cause of cancer-related death. The efficacy of GEM in combination with PS-targeted cancer-selective protein-lipid nanovesicles (SapC-DOPS) was studied in vitro and in PDAC mouse models.

Methods: MiaPaCa-2 subcutaneous PDAC tumors (100-300 mm3) were established in female athymic nude mice. Mice (12/group) were treated with GEM (40 mg/kg ip), SapC-DOPS (4.9 mg/kg iv), or both (GEM+SapC-DOPS) on day 26 and every 3 days thereafter. Tumor surface PS and size were analyzed at day 55. Orthotopic p53 2.1.1 tumors were generated in FVB/n mice and were confirmed by bioluminescence. 6 mice/group were treated with DOPS (1.9 mg/kg iv), GEM (10 mg/kg ip), SapC-DOPS (3 and 1.9 mg/kg iv), or GEM+SapC-DOPS 2x/week to day 55 and followed for survival. PS levels and cell death in vitro were confirmed by flow cytometry and MTT assay, respectively at 24-48 hr after GEM (10 nM-1 μM) in human AsPC-1, MiaPaCa-2, murine p53 2.1.1 PDAC, and immortalized human pancreatic duct epithelial cells.

Results: Elevated PS surface expression on viable PDAC cells was confirmed 48 hr after GEM in vitro and in subcutaneous tumors. Cancer cell death was notably higher in GEM+SapC-DOPS treated mice compared to GEM or SapC-DOPS alone (75.5±2.1% vs. 25.0±1.5% and 17.3±5.1%, respectively). SapC-DOPS+GEM more effectively inhibited tumor growth in both subcutaneous and orthotopic xenograft models compared to GEM alone. SapC-DOPS+GEM improved survival vs. either drug alone.

Conclusions: The combination of GEM and SapC-DOPS demonstrated enhanced antitumor activity in PDAC. This suggests that targeting externalized PS combined with chemotherapy is an effective means of selectively inducing tumor cell death, providing support for clinical study.

Title:
Combined Effect of Gemcitabine (GEM) and SapC-DOPS Nanovesicles on Pancreatic Ductal Adenocarcinoma (PDAC) in Mice.

Submitter’s E-mail Address:
ajohnson@ctifacts.com

Is this a late-breaking data submission?
If necessary, you can make changes to your abstract between now and the deadline of Tuesday, February 13, 2018

- To access your submission in the future, use the direct link to your abstract submission from one of the automatic confirmation emails that were sent to you during the submission.
- Or point your browser to asco/reminder.cgi to have that URL mailed to you again. Your username/password are 218487/931898.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.

Tell us what you think of the abstract submission process

Home Page